242 related articles for article (PubMed ID: 26005508)
21. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2.
Masaki I; Yonemitsu Y; Yamashita A; Sata S; Tanii M; Komori K; Nakagawa K; Hou X; Nagai Y; Hasegawa M; Sugimachi K; Sueishi K
Circ Res; 2002 May; 90(9):966-73. PubMed ID: 12016262
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic angiogenesis in critical limb and myocardial ischemia.
Vale PR; Isner JM; Rosenfield K
J Interv Cardiol; 2001 Oct; 14(5):511-28. PubMed ID: 12053643
[TBL] [Abstract][Full Text] [Related]
23. The impact of isolated tibial disease on outcomes in the critical limb ischemic population.
Gray BH; Grant AA; Kalbaugh CA; Blackhurst DW; Langan EM; Taylor SA; Cull DL
Ann Vasc Surg; 2010 Apr; 24(3):349-59. PubMed ID: 20045628
[TBL] [Abstract][Full Text] [Related]
24. Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non-reconstructable peripheral arterial disease.
Sen I; Agarwal S; Tharyan P; Forster R
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD009366. PubMed ID: 29658630
[TBL] [Abstract][Full Text] [Related]
25. The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia.
Belch JJ; Ray S; Rajput-Ray M; Engeset J; Fagrell B; Lepäntalo M; McKay A; Mackay IR; Ostergren J; Ruckley CV; Salenius J
Int Angiol; 2011 Apr; 30(2):150-5. PubMed ID: 21427652
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic angiogenesis induced by hepatocyte growth factor: potential gene therapy for ischemic diseases.
Aoki M; Morishita R; Taniyama Y; Kaneda Y; Ogihara T
J Atheroscler Thromb; 2000; 7(2):71-6. PubMed ID: 11426585
[TBL] [Abstract][Full Text] [Related]
27. PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial.
Norgren L; Weiss N; Nikol S; Hinchliffe RJ; Lantis JC; Patel MR; Reinecke H; Ofir R; Rosen Y; Peres D; Aberman Z
Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):538-545. PubMed ID: 30686676
[TBL] [Abstract][Full Text] [Related]
28. Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI).
Amann B; Lüdemann C; Rückert R; Lawall H; Liesenfeld B; Schneider M; Schmidt-Lucke J
Vasa; 2008 Nov; 37(4):319-25. PubMed ID: 19003741
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic angiogenesis for critical limb ischemia.
Ko SH; Bandyk DF
Semin Vasc Surg; 2014 Mar; 27(1):23-31. PubMed ID: 25812756
[TBL] [Abstract][Full Text] [Related]
30. The expression profile of angiogenic genes in critical limb ischemia popliteal arteries.
Baczynska D; Michalowska D; Barc P; Skora J; Karczewski M; Sadakierska-Chudy A
J Physiol Pharmacol; 2016 Jun; 67(3):353-62. PubMed ID: 27511996
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy and cell-based therapies for therapeutic angiogenesis in peripheral artery disease.
Shimamura M; Nakagami H; Koriyama H; Morishita R
Biomed Res Int; 2013; 2013():186215. PubMed ID: 24294599
[TBL] [Abstract][Full Text] [Related]
32. Translational Relevance of Advanced Age and Atherosclerosis in Preclinical Trials of Biotherapies for Peripheral Artery Disease.
Webster KA
Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38275616
[TBL] [Abstract][Full Text] [Related]
33. Insights into gene therapy for critical limb ischemia: the devil is in the details.
Madonna R; Rokosh G
Vascul Pharmacol; 2012 Aug; 57(1):10-4. PubMed ID: 22580542
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Potential of Adipose-Derived Therapeutic Factor Concentrate for Treating Critical Limb Ischemia.
Procházka V; Jurčíková J; Laššák O; Vítková K; Pavliska L; Porubová L; Buszman PP; Krauze A; Fernandez C; Jalůvka F; Špačková I; Lochman I; Jana D; Merfeld-Clauss S; March KL; Traktuev DO; Johnstone BH
Cell Transplant; 2016; 25(9):1623-1633. PubMed ID: 26525042
[TBL] [Abstract][Full Text] [Related]
35. Bmal1 Downregulation Worsens Critical Limb Ischemia by Promoting Inflammation and Impairing Angiogenesis.
Xu L; Liu Y; Cheng Q; Shen Y; Yuan Y; Jiang X; Li X; Guo D; Jiang J; Lin C
Front Cardiovasc Med; 2021; 8():712903. PubMed ID: 34447794
[TBL] [Abstract][Full Text] [Related]
36. [Overview on diagnosis, treatment and therapeutic angiogenesis for arteriosclerosis obliterans].
Ozaki K; Morishita R; Ogihara T
Nihon Rinsho; 2006 Nov; 64(11):2045-51. PubMed ID: 17087295
[TBL] [Abstract][Full Text] [Related]
37. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia.
Wang SK; Green LA; Motaganahalli RL; Wilson MG; Fajardo A; Murphy MP
J Vasc Surg; 2017 Jun; 65(6):1850-1857.e2. PubMed ID: 28390770
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease.
Taniyama Y; Morishita R; Aoki M; Nakagami H; Yamamoto K; Yamazaki K; Matsumoto K; Nakamura T; Kaneda Y; Ogihara T
Gene Ther; 2001 Feb; 8(3):181-9. PubMed ID: 11313789
[TBL] [Abstract][Full Text] [Related]
39. The Efficacy of HGF/VEGF Gene Therapy for Limb Ischemia in Mice with Impaired Glucose Tolerance: Shift from Angiogenesis to Axonal Growth and Oxidative Potential in Skeletal Muscle.
Stafeev I IS; Boldyreva MA; Michurina SS; Agareva MY; Radnaeva AV; Menshikov MY; Hu YC; Makarevich PI; Parfyonova YV
Cells; 2022 Nov; 11(23):. PubMed ID: 36497083
[TBL] [Abstract][Full Text] [Related]
40. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.
Morishita R; Aoki M; Hashiya N; Makino H; Yamasaki K; Azuma J; Sawa Y; Matsuda H; Kaneda Y; Ogihara T
Hypertension; 2004 Aug; 44(2):203-9. PubMed ID: 15238569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
